Dual Metabolic Defects Tied to Hypertriglyceridemia in Obese
Increased secretion and impaired VLDL1 clearance implicated in obese men
MONDAY, July 25 (HealthDay News) -- Hypertriglyceridemia in obese men can be attributed to dual metabolic defects of increased secretion and impaired clearance of triglyceride-rich very-low-density lipoprotein1 (VLDL1), according to a study published online July 21 in Arteriosclerosis, Thrombosis, and Vascular Biology.
Marja-Riitta Taskinen, M.D., Ph.D., from the University of Helsinki in Finland, and colleagues aimed to clarify the mechanisms that induce dyslipidemia in obese subjects. Pathophysiology of dyslipidemia was elucidated with the help of stable isotope tracers in 14 hypertriglyceridemic and 14 normotriglyceridemic obese men (with comparable body mass index and visceral fat volume), and in 10 normotriglyceridemic nonobese men. Proton magnetic resonance spectroscopy was used to assess liver fat and magnetic resonance imaging was used to assess subcutaneous abdominal and visceral fat.
The investigators found increased levels of serum triglycerides in the obese patients, which could be attributed to increased secretion and severely impaired clearance of VLDL1 particles. Increased liver and subcutaneous abdominal fat correlated with an increased secretion of VLDL1, while impaired clearance in obese hypertriglyceridemic individuals was associated with increased plasma levels of apolipoprotein C-III.
"Our results show that the hypertriglyceridemia is explained by the combination of increased secretion and severely impaired clearance of triglyceride-rich VLDL1 particles," the authors write.